Flavian Brown, Ph.D., serves as Principal Scientist at GV20 Therapeutics, where he leverages his extensive expertise in immunology to drive innovative research and development initiatives in the field of biologics for immuno-oncology. In his current role, Flavian is at the forefront of target validation and...
Flavian Brown, Ph.D., serves as Principal Scientist at GV20 Therapeutics, where he leverages his extensive expertise in immunology to drive innovative research and development initiatives in the field of biologics for immuno-oncology. In his current role, Flavian is at the forefront of target validation and translational sciences, leading the biological aspects of discovery projects from initial target evaluation through to lead identification and mechanism of action delineation. His deep understanding of immunometabolism and T cell biology enables him to design and execute robust oncological and immunological studies, both in vitro and in vivo, ensuring that the therapeutic candidates developed at GV20 are grounded in solid scientific principles.
As the lead translational scientist for the clinical asset GV20-0251, Flavian plays a pivotal role in bridging the gap between laboratory research and clinical application. His responsibilities encompass the planning and execution of comprehensive studies that assess the pharmacodynamics and pharmacokinetics of novel biologics, utilizing advanced techniques such as flow cytometry, ELISA, and intracellular cytokine staining. Flavian's proficiency in cell culture and mouse handling further enhances his ability to investigate the complex interactions within the tumor microenvironment, particularly the role of stromal cells in modulating immune responses.
Flavian's commitment to advancing the field of immuno-oncology is evident in his collaborative approach, working closely with cross-functional teams to translate scientific insights into effective therapeutic strategies. His leadership in target validation not only drives the success of GV20 Therapeutics but also contributes to the broader mission of developing innovative treatments that harness the power of the immune system to combat cancer.
